Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study*

Usefulness of Risk Scores to Estimate the Risk of Cardiovascular Disease in Patients With Rheumatoid Arthritis

(2012) Cynthia S. Crowson et al.   AMERICAN JOURNAL OF CARDIOLOGY

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Statins accelerate the onset of collagen type II-induced arthritis in mice

(2012) Rob J Vandebriel et al.   ARTHRITIS RESEARCH & THERAPY

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

(2011) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

Mechanisms for the anti-inflammatory effects of statins

(2011) De-xiu Bu et al.   CURRENT OPINION IN LIPIDOLOGY

Current and novel therapeutics in the treatment of systemic lupus erythematosus

(2011) Cagri Yildirim-Toruner et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2011) Yoshiya Tanaka et al.   ARTHRITIS CARE & RESEARCH

Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives

(2010) G. D. Kitas et al.   ANNALS OF THE RHEUMATIC DISEASES

'Rac'-ing upstream to treat rheumatoid arthritis

(2010) Gary S Firestein   ARTHRITIS RESEARCH & THERAPY

Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

(2009) E Choy et al.   ANNALS OF THE RHEUMATIC DISEASES

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Treatment of rheumatoid arthritis: state of the art 2009

(2009) Ronald F. van Vollenhoven   Nature Reviews Rheumatology